glp-1 obesity cardiovascular news How are drugs reshaping treatment for obesity, diabetes, and heart disease? Glucagon-like peptide 1 receptor agonists:

After a two-year-long shortage, the FDA announced that Eli Lillys GLP-1 drug Mounjaro, and obesity version Zepbound, are back in stock.

Compare early results with Wegovy and Mounjaro.

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

#glp1 #weightlossjourney #haleonpartner #haleon #WellWithinReach #livehealthiHER @benefiber @tumsofficial

Learn more about GPCR stock here.

Smoothie King has decided to capitalize on the growing market of Ozempic users with a brand new menu designed for people taking GLP-1 medications.